Literature DB >> 25440592

Clinical outcome of isolated tricuspid regurgitation.

Yan Topilsky1, Vuyisile T Nkomo2, Ori Vatury2, Hector I Michelena2, Thierry Letourneau2, Rakesh M Suri3, Sorin Pislaru2, Soon Park3, Douglas W Mahoney4, Simon Biner1, Maurice Enriquez-Sarano5.   

Abstract

OBJECTIVES: The aim of this study was to assess the outcome of isolated tricuspid regurgitation (TR) and the added value of quantitative evaluation of its severity.
BACKGROUND: TR is of uncertain clinical outcome due to confounding comorbidities. Isolated TR (without significant comorbidities, structural valve disease, significant pulmonary artery systolic pressure elevation by Doppler, or overt cardiac cause) is of unknown clinical outcome.
METHODS: In patients with isolated TR assessed both qualitatively and quantitatively by a proximal isovelocity surface area method, a long-term outcome analysis was conducted. Patients with severe comorbid diseases were excluded.
RESULTS: The study involved 353 patients with isolated TR (age 70 years; 33% male; ejection fraction, 63%; all with right ventricular systolic pressure <50 mm Hg). Severe isolated TR was diagnosed in 76 patients (21.5%) qualitatively and 68 patients (19.3%) by quantitative criteria (effective regurgitant orifice [ERO] ≥40 mm(2)). The 10-year survival and cardiac event rates were 63 ± 5% and 29 ± 5%. Severe isolated TR independently predicted higher mortality (adjusted hazard ratio: 1.78 [95% confidence interval (CI): 1.10 to 2.82], p = 0.02 for qualitative definition and 2.67 [95% CI: 1.66 to 4.23] for an ERO ≥40 mm(2), p < 0.0001). The addition of grading by quantitative criteria in nested models eliminated the significance of the qualitative grading and improved the model prediction (p < 0.001 for survival and p = 0.02 for cardiac events). The 10-year survival rate was lower with an ERO ≥40 mm(2) versus <40 mm(2) (38 ± 7% vs. 70 ± 6%; p < 0.0001), independent of all characteristics, right ventricular size or function, comorbidity, or pulmonary pressure (p < 0.0001 for all), and lower than expected in the general population (p < 0.001). Freedom from cardiac events was lower with an ERO ≥40 mm(2) versus <40 mm(2) independently of all characteristics, right ventricular size or function, comorbidity, or pulmonary pressure (p < 0.0001 for all). Cardiac surgery for severe isolated TR was rarely performed (16 ± 5% 5 years after diagnosis).
CONCLUSIONS: Isolated TR can be severe and is associated with excess mortality and morbidity, warranting heightened attention to diagnosis and quantitation. Quantitative assessment of TR, particularly ERO measurement, is a powerful independent predictor of outcome, superior to standard qualitative assessment.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  effective regurgitant orifice; isolated tricuspid regurgitation; prognosis; tricuspid regurgitation

Mesh:

Year:  2014        PMID: 25440592     DOI: 10.1016/j.jcmg.2014.07.018

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  57 in total

1.  Tricuspid Regurgitation: 2015 Reflections and Re-evaluation.

Authors:  Julia Grapsa; Lawrence Rudski
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-10

Review 2.  Percutaneous tricuspid valve implantation in failing bioprosthesis.

Authors:  Andreas Eicken; Peter Ewert
Journal:  Cardiovasc Diagn Ther       Date:  2018-12

Review 3.  Non-functional tricuspid valve disease.

Authors:  Dale S Adler
Journal:  Ann Cardiothorac Surg       Date:  2017-05

4.  Three-dimensional echocardiography investigation of the mechanisms of tricuspid annular dilatation.

Authors:  Valentina Volpato; Victor Mor-Avi; Federico Veronesi; Karima Addetia; Megan Yamat; Lynn Weinert; Davide Genovese; Gloria Tamborini; Mauro Pepi; Roberto M Lang
Journal:  Int J Cardiovasc Imaging       Date:  2019-08-20       Impact factor: 2.357

5.  The impact of tricuspid annular geometry on outcome after percutaneous edge-to-edge repair for severe tricuspid regurgitation.

Authors:  Sylvia Otto; Marija Velichkov; Ali Hamadanchi; P Christian Schulze; Sven Moebius-Winkler
Journal:  Cardiol J       Date:  2021-05-04       Impact factor: 2.737

Review 6.  [Tricuspid valve regurgitation : Indications and operative techniques].

Authors:  R Lange; N Piazza; T Günther
Journal:  Herz       Date:  2017-11       Impact factor: 1.443

Review 7.  Current Treatment Strategies for Tricuspid Regurgitation.

Authors:  Mohammed Al-Hijji; Erin A Fender; Abdallah El Sabbagh; David R Holmes
Journal:  Curr Cardiol Rep       Date:  2017-09-14       Impact factor: 2.931

8.  Comprehensive Two-Dimensional Interrogation of the Tricuspid Valve Using Knowledge Derived from Three-Dimensional Echocardiography.

Authors:  Karima Addetia; Megan Yamat; Anuj Mediratta; Diego Medvedofsky; Mita Patel; Preston Ferrara; Victor Mor-Avi; Roberto M Lang
Journal:  J Am Soc Echocardiogr       Date:  2015-09-28       Impact factor: 5.251

9.  Computed tomography for transcatheter tricuspid valve development.

Authors:  Paul-Matthieu Chiaroni; Julien Ternacle; Jean-François Deux; Madjid Boukantar; Gauthier Mouillet; Elisabeth Riant; Jean-Luc Dubois-Randé; Emmanuel Teiger; Pascal Lim; Romain Gallet
Journal:  Eur Radiol       Date:  2019-08-26       Impact factor: 5.315

10.  Outcomes of Guideline-Directed Concomitant Annuloplasty for Functional Tricuspid Regurgitation.

Authors:  Alexander A Brescia; Sarah T Ward; Tessa M F Watt; Liza M Rosenbloom; Megan Baker; Shazli Khan; Emilie Ziese; Matthew A Romano; Steven F Bolling
Journal:  Ann Thorac Surg       Date:  2019-08-31       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.